New roles of osteoblasts involved in osteoclast differentiation

Yamashita T et al . Osteoblasts and osteoclast differentiation7 Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, BurgessT, Elliott R, Colombero A, Elliott G, Scully S, Hsu H,Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, QianYX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, DelaneyJ, Boyle WJ. Osteoprotegerin ligand is a cytokine thatregulates osteoclast differentiation and activation. Cell 1998;93: 165-1768 Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, YoshidaH, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF,Mak TW, Kodama T, Taniguchi T. Induction and activationof the transcription factor NFATc1 (NFAT2) integrateRANKL signaling in terminal differentiation of osteoclasts.Dev Cell 2002; 3: 889-9019 Simonet WS, Lacey DL, Dunstan CR, Kelley M, ChangMS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, BooneT, Shimamoto G, DeRose M, Elliott R, Colombero A, TanHL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L,Hughes TM, Hill D, Pattison W, Campbell P, Sander S, VanG, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: anovel secreted protein involved in the regulation of bonedensity. Cell 1997; 89: 309-31910 Yasuda H, Shima N, Nakagawa N, Mochizuki SI, YanoK, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M,Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K.Identity of osteoclastogenesis inhibitory factor (OCIF) andosteoprotegerin (OPG): a mechanism by which OPG/OCIFinhibits osteoclastogenesis in vitro. Endocrinology 1998; 139:1329-133711 Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, CapparelliC, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W,Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ,Penninger JM. OPGL is a key regulator of osteoclastogenesis,lymphocyte development and lymph-node organogenesis.Nature 1999; 397: 315-32312 Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, Mc-Cabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, SunY, Tarpley J, Martin L, Christensen K, McCabe J, KostenuikP, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ.RANK is the intrinsic hematopoietic cell surface receptorthat controls osteoclastogenesis and regulation of bone massand calcium metabolism. Proc Natl Acad Sci USA 2000; 97:1566-157113 Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, CapparelliC, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, SimonetWS. osteoprotegerin-deficient mice develop early onsetosteoporosis and arterial calcification. Genes Dev 1998; 12:1260-126814 Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, KannoT, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, GomibuchiT, Yano K, Shima N, Washida N, Tsuda E, Morinaga T,Higashio K, Ozawa H. Severe osteoporosis in mice lackingosteoclastogenesis inhibitory factor/osteoprotegerin. BiochemBiophys Res Commun 1998; 247: 610-61515 Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R,Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, CallonKE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J. Amutation in the gene TNFRSF11B encoding osteoprotegerincauses an idiopathic hyperphosphatasia phenotype. HumMol Genet 2002; 11: 2119-212716 Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H,Coker M, Kanis J, Seidel J, Tau C, Tüysüz B, Yüksel B, LoveD. Idiopathic hyperphosphatasia and TNFRSF11B mutations:relationships between phenotype and genotype. JBone Miner Res 2003; 18: 2095-210417 Whyte MP, Obrecht SE, Finnegan PM, Jones JL, PodgornikMN, McAlister WH, Mumm S. Osteoprotegerin deficiencyand juvenile Paget’s disease. N Engl J Med 2002; 347: 175-18418 Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H,Wallace RG, van Hul W, Whyte MP, Nakatsuka K, HovyL, Anderson DM. Mutations in TNFRSF11A, affecting thesignal peptide of RANK, cause familial expansile osteolysis.Nat Genet 2000; 24: 45-4819 Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS,Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J,Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D,Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, VezzoniP, Villa A, Frattini A. Human osteoclast-poor osteopetrosiswith hypogammaglobulinemia due to TNFRSF11A (RANK)mutations. Am J Hum Genet 2008; 83: 64-7620 Sobacchi C, Frattini A, Guerrini MM, Abinun M, PangrazioA, Susani L, Bredius R, Mancini G, Cant A, Bishop N,Grabowski P, Del Fattore A, Messina C, Errigo G, CoxonFP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, HelfrichMH. Osteoclast-poor human osteopetrosis due to mutationsin the gene encoding RANKL. Nat Genet 2007; 39: 960-96221 Mizoguchi T, Muto A, Udagawa N, Arai A, YamashitaT, Hosoya A, Ninomiya T, Nakamura H, Yamamoto Y,Kinugawa S, Nakamura M, Nakamichi Y, Kobayashi Y, NagasawaS, Oda K, Tanaka H, Tagaya M, Penninger JM, Ito M,Takahashi N. Identification of cell cycle-arrested quiescentosteoclast precursors in vivo. J Cell Biol 2009; 184: 541-55422 Muto A, Mizoguchi T, Udagawa N, Ito S, Kawahara I,Abiko Y, Arai A, Harada S, Kobayashi Y, Nakamichi Y, PenningerJM, Noguchi T, Takahashi N. Lineage-committedosteoclast precursors circulate in blood and settle down intobone. J Bone Miner Res 2011; 26: 2978-299023 Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, HalenbeckR, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T,Qin M, Wong J, Chu K, Doberstein SK, Williams LT. Discoveryof a cytokine and its receptor by functional screening ofthe extracellular proteome. Science 2008; 320: 807-81124 Chihara T, Suzu S, Hassan R, Chutiwitoonchai N, HiyoshiM, Motoyoshi K, Kimura F, Okada S. IL-34 and M-CSF sharethe receptor Fms but are not identical in biological activityand signal activation. Cell Death Differ 2010; 17: 1917-192725 Chen Z, Buki K, Vääräniemi J, Gu G, Väänänen HK. Thecritical role of IL-34 in osteoclastogenesis. PLoS One 2011; 6:e1868926 Nakamichi Y, Mizoguchi T, Arai A, Kobayashi Y, SatoM, Penninger JM, Yasuda H, Kato S, DeLuca HF, Suda T,Udagawa N, Takahashi N. Spleen serves as a reservoir ofosteoclast precursors through vitamin D-induced IL-34expression in osteopetrotic op/op mice. Proc Natl Acad SciUSA 2012; 109: 10006-1001127 Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M,Saeki Y, Vacher J, Proia RL, Germain RN. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulatesbone homeostasis. Nature 2009; 458: 524-52828 Arai A, Mizoguchi T, Harada S, Kobayashi Y, NakamichiY, Yasuda H, Penninger JM, Yamada K, Udagawa N, TakahashiN. Fos plays an essential role in the upregulation ofRANK expression in osteoclast precursors within the bonemicroenvironment. J Cell Sci 2012; 125: 2910-291729 Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A,Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M,Marumo K, Martin TJ, Minami Y, Takahashi N. Wnt5a-Ror2signaling between osteoblast-lineage cells and osteoclastprecursors enhances osteoclastogenesis. Nat Med 2012; 18:405-41230 Gordon MD, Nusse R. Wnt signaling: multiple pathways,multiple receptors, and multiple transcription factors. J BiolChem 2006; 281: 22429-2243331 Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, ReginatoAM, Wang H, Cundy T, Glorieux FH, Lev D, ZacharinM, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G,Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, BatchJA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C,Brunner HG, Carle GF, Dallapiccola B, De Paepe A, FloegeB, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A,Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A,WJO|www.wjgnet.com180 November 18, 2012|Volume 3|Issue 11|